Acetic acid (7S,8R,9S,10R,13S,14S,17S)-7,10,13-trimethyl-3-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester | 50718-24-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Acetic acid (7S,8R,9S,10R,13S,14S,17S)-7,10,13-trimethyl-3-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester
• 英文别名: 7alpha-Methylandrost-5-en-3-on-17beta-ol 17 acetate；[(7S,8R,9S,10R,13S,14S,17S)-7,10,13-trimethyl-3-oxo-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
• CAS: 50718-24-6
• 化学式: C₂₂H₃₂O₃
• 分子量: 344.494
• InChiKey: DQDXVQAFSBPHJW-JTIIFYKTSA-N

物化性质

• 沸点：
  442.3±45.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Acetic acid (7S,8R,9S,10R,13S,14S,17S)-7,10,13-trimethyl-3-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester 、 硼氢化钠 、 溶剂黄146 在 ice 、 crude product 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 3.0h， 以to give 7α-methylandrost-5-ene-3β,17β-diol 17 acetate (L75a) as a white solid的产率得到7alpha-Methylandrost-5-ene-3beta,17beta-diol 17 acetate
  参考文献：
  名称：

  20-fluoro-17(20)-vinyl steroids

  摘要：

  本发明涉及20&xgr;-氟孕酮-4,17(20)-二烯-3-酮-21-油酸乙酯、20&xgr;-氟-3&bgr;-羟基孕酮-5,17(20)-二烯-21-油酸乙酯、20&xgr;-氟-21-羟基孕酮-4,17(20)-二烯-3-酮、20&xgr;-氟孕酮-5,17(20)-二烯-3&bgr;，21-二醇及其相关化合物，以及包含这些化合物的组合物，还涉及抑制C17,20裂解酶、5&agr;-还原酶和C17-羟化酶，以及将这些化合物用于治疗雄激素和雌激素介导或依赖性疾病，包括良性前列腺增生、前列腺癌、乳腺癌和DHT介导的疾病，如痤疮和多毛症。本发明还包括治疗与皮质醇过度合成相关的疾病，例如库欣综合征。雄激素依赖性疾病的治疗还包括与已知雄激素受体拮抗剂（如氟他胺）的联合治疗。本发明的化合物具有以下一般式：

  公开号：

  US06413951B2
• 作为产物：
  描述：

  androsta-4,6-dien-17β-ol-3-one acetate 、 甲基锂 生成 Acetic acid (7S,8R,9S,10R,13S,14S,17S)-7,10,13-trimethyl-3-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester 、 Acetic acid (7R,8R,9S,10R,13S,14S,17S)-7,10,13-trimethyl-3-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester
  参考文献：
  名称：

  Antiprogestational agents. The synthesis of 7-alkyl steroidal ketones with anti-implantational and antidecidual activity

  摘要：

  A series of 7alpha- and 7beta- alkyl derivatives of steroidal 4-en- and 5-en-3-ones were prepared by 1,6-conjugate addition of organocopper reagents to various steroidal 4,6-dien-3-ones of the androstane, estrane and gonane series. Biological study of these and related compounds revealed that 17beta-hydroxy-7alpha-methyl-5-androsten-3-one (2), 17beta-hydroxy-7alpha-methyl-5-estren-3-one acetate and 17beta-hydroxy-7alpha-methyl-4-estren-3-one acetate had significant anti-implantational and antidecidual activities. The contragestative effects were associated with the latter anti-hormonal properties, and not with the androgenicity of these compounds.

  DOI：

  10.1016/0039-128x(76)90136-7

文献信息

• 20-Fluoro-17(20)-vinyl steroids
  申请人：——

  公开号：US20020019548A1

  公开（公告）日：2002-02-14

  The invention related to 20&xgr;-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester, 20&xgr;-fluoro-3&bgr;-hydroxypregna-4,17(20)-dien-21-oic acid ethyl ester, 20&xgr;-fluoro-21-hydroxypregna-4,17(20)-dien-3-one, 20&xgr;-fluoropregna-4,17(20)-dien-3&bgr;,21-diol and related compounds and to compositions incorporating these compounds, as well as the inhibition of C 17,20 lyase, 5&agr;-reductase and C 17 -hydroxylase, and to the use of these compounds in the treatment of androgen and estrogen mediated or dependent disorders, including benign prostatic hyperplasia, prostate cancer, breast cancer and DHT-mediated disorders such as acne and hirsutism. Treatment of disorders related to the over synthesis of cortisol, for example, Cushing's Syndrome are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have the following general formulae: 1

  本发明涉及20&xgr;-氟孕-4,17（20）-二烯-3-酮-21-羧酸乙酯，20&xgr;-氟-3&bgr;-羟基孕-4,17（20）-二烯-21-羧酸乙酯，20&xgr;-氟-21-羟基孕-4,17（20）-二烯-3-酮，20&xgr;-氟孕-4,17（20）-二烯-3&bgr;，21-二醇及其相关化合物，以及包含这些化合物的组合物，以及抑制C17,20裂解酶、5&agr;-还原酶和C17-羟化酶，并将这些化合物用于治疗雄激素和雌激素介导或依赖性疾病，包括良性前列腺增生症、前列腺癌、乳腺癌和DHT介导的疾病，如痤疮和多毛症。本发明还包括治疗与皮质醇过度合成有关的疾病，例如库欣综合征。雄激素依赖性疾病的治疗还包括与已知雄激素受体拮抗剂（如氟他胺）的联合治疗。本发明的化合物具有以下一般式：1